StockData

Altimmune vs Incannex Healthcare

ALT and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALT and IXHL compare

Altimmune is the larger company, worth 13 times as much as Incannex Healthcare ($320M against $24.7M).

Incannex Healthcare scores higher on the StockData Score (7 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALTIXHL
Size and price
Market cap$320M$24.7M
Share price$1.65$1.97
Change, 1 year−61.1%−82.4%
Change, 5 years−84.4%–
Beta (5Y)1.071.95
Employees1312
StockData Score
Total score47 (better)
Valuation score11
Growth score00
Performance score11
Health score25 (better)
Dividend score00
Valuation
P/B0.7×0.4× (better)
FCF yield−32.0% (better)−52.1%
Growth
Revenue growth, 5Y average−65.3%–
Profitability
Return on equity−33.2% (better)−47.8%
Return on invested capital−89.7%–
Financial health
Debt / equity0.08 (better)0.00
Interest coverage−27.6×–
Current ratio23.9348.81 (better)
Altman Z-score1.51 (better)−0.62
Piotroski F-score44
Dividends and buybacks
Buyback yield−22.1% (better)−280%
Shareholder yield−22.1% (better)−280%
Ownership
Held by institutions77.9%3.6%
Held by insiders0.51%–
Insider net buying, 12 months$370K–
Superinvestors holding1–
Short interest, % of float21.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.